-+ 0.00%
-+ 0.00%
-+ 0.00%

Investors Shouldn't Be Too Comfortable With Wonbiogen's (KOSDAQ:307280) Earnings

Simply Wall St·11/20/2026 23:32:11
Listen to the news

Wonbiogen Co., Ltd.'s (KOSDAQ:307280) stock was strong after they recently reported robust earnings. We did some analysis and think that investors are missing some details hidden beneath the profit numbers.

earnings-and-revenue-history
KOSDAQ:A307280 Earnings and Revenue History November 20th 2026

A Closer Look At Wonbiogen's Earnings

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.

That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

Wonbiogen has an accrual ratio of 0.35 for the year to September 2026. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us doubt the utility of profit as a guide. Even though it reported a profit of ₩8.61b, a look at free cash flow indicates it actually burnt through ₩3.2b in the last year. We saw that FCF was ₩7.1b a year ago though, so Wonbiogen has at least been able to generate positive FCF in the past. The good news for shareholders is that Wonbiogen's accrual ratio was much better last year, so this year's poor reading might simply be a case of a short term mismatch between profit and FCF. As a result, some shareholders may be looking for stronger cash conversion in the current year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Wonbiogen.

Our Take On Wonbiogen's Profit Performance

As we discussed above, we think Wonbiogen's earnings were not supported by free cash flow, which might concern some investors. For this reason, we think that Wonbiogen's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But the good news is that its EPS growth over the last three years has been very impressive. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example, Wonbiogen has 3 warning signs (and 1 which is a bit unpleasant) we think you should know about.

Today we've zoomed in on a single data point to better understand the nature of Wonbiogen's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.